Display Settings:

Format

Send to:

Choose Destination
    Mol Ther. 2009 Jul;17(7):1241-9. Epub 2009 Apr 14.

    Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases.

    Source

    Department of Surgery, McGill University, Montreal, Quebec, Canada.

    Abstract

    Liver metastases respond poorly to current therapy and remain a frequent cause of cancer-related mortality. We reported previously that tumor cells expressing a soluble form of the insulin-like growth factor-I receptor (sIGFIR) lost the ability to metastasize to the liver. Here, we sought to develop a novel therapeutic approach for prevention of hepatic metastasis based on sustained in vivo delivery of the soluble receptor by genetically engineered autologous bone marrow stromal cells. We found that when implanted into mice, these cells secreted high plasma levels of sIGFIR and inhibited experimental hepatic metastases of colon and lung carcinoma cells. In hepatic micrometastases, a reduction in intralesional angiogenesis and increased tumor cell apoptosis were observed. The results show that the soluble receptor acted as a decoy to abort insulin-like growth factor-I receptor (IGF-IR) functions during the early stages of metastasis and identify sustained sIGFIR delivery by cell-based vehicles as a potential approach for prevention of hepatic metastasis.

    PMID:
    19367255
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2835215
    Free PMC Article

    Images from this publication.See all images (6) Free text

    Figure 3
    Figure 1
    Figure 5
    Figure 2
    Figure 4
    Figure 6

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk